JPMorgan Chase & Co. Has $90,000 Stake in ProKidney Corp. (NASDAQ:PROK)

JPMorgan Chase & Co. raised its position in ProKidney Corp. (NASDAQ:PROK) by 65.1% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 46,830 shares of the company’s stock after purchasing an additional 18,472 shares during the quarter. JPMorgan Chase & Co.’s holdings in ProKidney were worth $90,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Suvretta Capital Management LLC increased its position in shares of ProKidney by 32.1% in the third quarter. Suvretta Capital Management LLC now owns 12,341,266 shares of the company’s stock valued at $23,695,000 after acquiring an additional 3,000,000 shares during the last quarter. Geode Capital Management LLC increased its position in shares of ProKidney by 102.0% in the third quarter. Geode Capital Management LLC now owns 2,203,934 shares of the company’s stock valued at $4,232,000 after acquiring an additional 1,112,933 shares during the last quarter. Charles Schwab Investment Management Inc. increased its position in shares of ProKidney by 150.6% in the third quarter. Charles Schwab Investment Management Inc. now owns 749,718 shares of the company’s stock valued at $1,439,000 after acquiring an additional 450,548 shares during the last quarter. State Street Corp increased its position in shares of ProKidney by 16.2% in the third quarter. State Street Corp now owns 1,428,318 shares of the company’s stock valued at $2,742,000 after acquiring an additional 198,836 shares during the last quarter. Finally, Barclays PLC increased its position in shares of ProKidney by 575.7% in the third quarter. Barclays PLC now owns 146,321 shares of the company’s stock valued at $281,000 after acquiring an additional 124,667 shares during the last quarter. Institutional investors and hedge funds own 51.59% of the company’s stock.

ProKidney Stock Performance

NASDAQ:PROK opened at $1.65 on Monday. The stock’s 50-day simple moving average is $1.77 and its 200 day simple moving average is $1.95. The company has a market cap of $481.24 million, a P/E ratio of -3.00 and a beta of 1.32. ProKidney Corp. has a 52-week low of $1.18 and a 52-week high of $4.44.

ProKidney (NASDAQ:PROK) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($0.14) EPS for the quarter, hitting analysts’ consensus estimates of ($0.14). As a group, equities analysts predict that ProKidney Corp. will post -0.57 earnings per share for the current fiscal year.

ProKidney Company Profile

ProKidney Corp., a clinical-stage biotechnology company, provides transformative proprietary cell therapy platform for treating various chronic kidney diseases in the United States. The company's lead product is Renal Autologous Cell Therapy (REACT), an autologous homologous cell admixture, which has completed Phase I clinical trial for REACT in patients with congenital anomalies of the Kidney and Urinary Tract (CAKUT), as well as in Phase III and Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease.